Locations:
Search IconSearch
November 24, 2020/Cancer

Small-Incision Guarded Hydroaspiration in Patient with Small Iris Lesion

35-year-old presents with suspected iris melanoma

20-EYE-1989584-CQD-Case-study-melanoma-Iris-Hero

A 35-year-old presented at Cole Eye Institute with a lesion in the left iris. He had been seen annually by an outside optometrist for seven years. The lesion had not been noted previously.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

The patient did not have any visual symptoms, and his visual acuity was 20/20 in both eyes.

The elevated pigmented lesion in the iris was associated with nodularity along the pupillary margin between the 10- and 11-o’clock position. There were no feeder vessels or neovascularization of the iris on exam.

OCT

Anterior segment OCT showed multinodular iris thickening.

Lesion

Although the lesion was small and appeared like a nevus, melanoma was suspected due to recent onset.

“Freckles and nevi of the iris are very common,” says Arun D. Singh, MD, Director of Ophthalmic Oncology at Cole Eye Institute. “All spots aren’t malignant, but there are some clues that can indicate which spots likely are.”

According to Dr. Singh, iris lesions suspicious for melanoma are those that:

  • Are newly detected or recently changed.
  • Distort the iris more than 3 mm in any dimension. “If it’s simply sitting on the iris, like a paint spot, we’re more apt to think it’s benign,” says Dr. Singh.
  • Contain blood vessels.
  • Have nodular elevations.

Excisional biopsy with pupilloplasty

Following discussion of treatment options, the patient agreed to undergo excisional biopsy of the lesion with pupilloplasty using a small-incision approach.

Conventionally, iris resection for a suspected malignancy has involved a large incision in the cornea and sclera and the removal of 25% or more of the iris. This sector iridectomy has been associated with increased risk of wound-related complications, tumor seeding and recurrence, and photophobia due to iris defect.

Almost 15 years ago, Dr. Singh developed a new technique: small-incision guarded hydroaspiration (SINGH procedure). Instead of one large incision, there are multiple small incisions. After excising the tumor, plastic tubing containing a sodium hyaluronate solution is inserted into the anterior chamber. Using a syringe, the excised lesion is pulled into the tube, where it is isolated and removed safely as the tube is withdrawn from the anterior chamber. This prevents the tumor from being pulled across the wound, possibly shedding cells and seeding the edges of the wound.

Advertisement

The next step, pupilloplasty, restores the iris to a near-normal shape with a suturing slip-knot technique since the iris does not have capacity to heal. This restoration of the iris not only repairs the cosmetic defect but helps prevent photophobia.

“Healing was much slower — six weeks or longer — with conventional techniques using the larger incision,” says Dr. Singh. “Distortion of the cornea was a problem too. If you’d make a 6 mm wound in the cornea, it would be irregular when it healed. Multiple smaller incisions allow faster healing. Patients typically have normal vision within a week or so.”

In this case, as clinically suspected, histopathology confirmed iris melanoma. All surgical margins were negative.

One day later, the patient’s vision was 20/30 with minimal postoperative inflammation.

Post-surgery

Four weeks following surgery, the patient’s vision was normal (20/20) without change in corneal astigmatism. The pupil size was equal between the two eyes in ambient light.

Patient eye

Now three years since surgery, the patient remains recurrence-free.

Three years postop

Better risk-benefit ratio than conventional iridectomy

Melanoma of the uvea is rare, occurring in just six per 1 million people. Approximately 10% of uveal melanoma occurs in the iris — extremely rare.

Two decades ago, the only option for removing uveal melanoma was an iridectomy with a large corneoscleral incision, requiring six weeks or more of healing and slow visual recovery. New techniques and better instrumentation now provide another option, with a better risk-benefit ratio, says Dr. Singh.

“Today, if I see a lesion growing, I recommend we remove it because I know we can do so safely with minimally invasive techniques,” he says. “In the past, we would just watch the lesion and hope to avoid a big surgery.”

Advertisement

Even small lesions can be suspicious for melanoma, which can be removed easily with low risk to the patient, he concludes.

Advertisement

Related Articles

Dr. Khorana
April 25, 2025/Cancer/News & Insight
Molecular Insights into Early-Onset Biliary Tract Cancer (Podcast)

A call for awareness about the importance of genomic testing

Dr. Melenhorst
April 24, 2025/Cancer/News & Insight
Explore Developments in CAR T-Cell Therapy for CLL (Podcast)

Discussing research into improving CAR T-cell therapy efficacy

Dr. Cherian
April 23, 2025/Cancer/News & Insight
De-intensifying Radiation Therapy in Low-Risk Breast Cancer

Ultra-Hypofractionated Whole Breast Irradiation and Partial Breast Irradiation Reduce Many Toxicities

Pathology image
April 22, 2025/Cancer/News & Insight
Patient Case Study: Second Opinion Reveals Misdiagnosed Cancer

Patient receives liver transplant and a new lease on life

Clinician talking with patient
April 21, 2025/Cancer/News & Insight
Hematology Clinic Created to Support Spanish-Speaking Population

Lutheran Hospital team brings emerging treatments to community setting

Dr. Pennell and patient
April 10, 2025/Cancer/News & Insight
BiTE Therapy Emerges for Treating Small-Cell Lung Cancer

Hybrid treatment model helps improve cancer care access

Immune checkpoint inhibitor illustration
April 8, 2025/Cancer
Building on Initial Trial Data about New Immune Checkpoint Inhibitor for Treating Colorectal Cancer

Insights indicate that treatment may be beneficial beyond MSI-H tumors

Dr. Gerds with a patient
April 7, 2025/Cancer/News & Insight
Positive Results from Prospective, Randomized, Phase 3 Registrational Trial of Pelabresib + Ruxolitinib for JAK Inhibitor-Naive Myelofibrosis

Combination therapy doubles the number of meaningful spleen volume responses over monotherapy

Ad